Login to Your Account

Pazdur Deconstructs Avastin Decision

PFS Coming Into Its Own, but Just One Factor in Avastin OK

By Trista Morrison

Monday, March 3, 2008
Now that the initial surprise has worn off regarding the FDA's decision to grant accelerated approval for Genentech Inc.'s Avastin (bevacizumab) in breast cancer, the industry can begin to digest the implications of that decision. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription